載入中
NASDAQHealthcareBiotechnology
最新資料
US$150.23
−US$5.42 · -3.48%
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
一般交易時段
US$150.11
−US$5.545 · -3.56%
盤中時間採用ET。市場資料可能有所延遲。
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
日內區間
目前US$150.11
52週區間
目前US$150.11
盤中時間採用ET。市場資料可能有所延遲。
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
日內區間
目前US$150.11
52週區間
目前US$150.11
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.77億 USD | 3.13億 USD | 2.45億 USD | 2.04億 USD | 1.32億 USD |
| 銷貨成本 | 1.86億 USD | 1.8億 USD | 1.55億 USD | 1.19億 USD | 8062萬 USD |
| 毛利 | 1.91億 USD | 1.33億 USD | 8972.9萬 USD | 8423.5萬 USD | 5171.3萬 USD |
| 研究與開發 | 8028.5萬 USD | 9085.2萬 USD | 1.07億 USD | 1.2億 USD | 6907.2萬 USD |
| 銷售、一般及管理費用 | 2.47億 USD | 2.18億 USD | 1.9億 USD | 2.13億 USD | 1.36億 USD |
| 營業費用 | 3.27億 USD | 3.54億 USD | 3.07億 USD | 3.19億 USD | 2.04億 USD |
| 利息收入 | 1136.4萬 USD | 1534.4萬 USD | 1436.5萬 USD | 306.2萬 USD | 43.5萬 USD |
| 利息支出 | — | 2.9萬 USD | 5000 USD | 8萬 USD | 36.7萬 USD |
| 折舊和攤銷 | 2485.3萬 USD | 3143.2萬 USD | 2931萬 USD | 1651.4萬 USD | 975萬 USD |
| 營業利益 | −1.36億 USD | −2.21億 USD | −2.17億 USD | −2.35億 USD | −1.53億 USD |
| 淨利 | −7767萬 USD | −2.09億 USD | −2.05億 USD | −2.18億 USD | −1.52億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$145.2
下跌空間 3.27%報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK3.82億3.45%55.62億 USD0.75%US$88.145-0.18%
Vanguard Morningstar Total Stock Market ETFVTI2.77億0.01%2.3兆 USD0.03%US$380.23-0.21%
iShares Russell 2000 ETFIWM2.71億0.35%785.63億 USD0.19%US$275.72-0.71%
State Street SPDR S&P Biotech ETFXBI2.06億2.00%100.75億 USD0.35%US$146.97-2.17%
Vanguard Morningstar Small-Cap ETFVB2億0.11%1853億 USD0.03%US$285.8-0.41%
ARK Genomic Revolution ETFARKG1.83億8.65%15.57億 USD0.75%US$48.76-2.75%
Vanguard Morningstar Small-Cap Growth ETFVBK1.15億0.25%447億 USD0.05%US$339.97-0.66%
Vanguard Extended Market ETFVXF1.06億0.11%954億 USD0.05%US$232.28-0.52%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
